The 36-month overall survival rate was 74% in the belantamab mafodotin arm and 60% in the daratumumab arm. Belantamab ...
Adding pyrotinib to trastuzumab and docetaxel prolonged progression-free survival in patients with HER2-positive metastatic breast cancer.
Palbociclib plus ET improved outcomes over chemotherapy ± ET maintenance in patients with high-risk, HR+, HER2- metastatic breast cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback